<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221106056422N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-29</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>The comparative effect of Kinesio Taping method and Dry needling technique in plantar fasciitis</public_title>
      <acronym></acronym>
      <scientific_title>The comparative effect of Kinesio Taping method and Dry needling technique on pain, performance and plantar fascia thickness in patients with plantar fasciitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66821</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple non-probability sampling will be used in this study. The allocation of individuals to the three groups will be performed through random allocation and for such purpose the Block randomization will be used. This clinical trial study including 45 samples that will be randomly allocated in three groups (one group is control and two other groups are intervention1 and 2). The therapist divides subjects into subgroups called blocks with size of 3. Individuals in each block are randomly divided into three groups: control (C), treatment1(T1) and treatmet2 (T2). Hence we have a combination of control and treatment blocks as (T2T1C, T1T2C, T1CT2, CT2T1,  و  CT1T2, T2CT1). finally we randomly select 15 blocks using excel computer software. therefore we have had 45 subjects that in each groups will be 15 subjects. 
The number of blocks and how they are executed are done by hiding them inside the envelope. In this method, the blocks are numbered based on a random sequence and are placed inside the envelopes, and the researcher assigns them to the intervention and treatment groups based on the order of arrival of the patients, Blinding description: This study is Single-blind. Outcome assessor and analyzer will be blind and will not be aware from grouping. Groups will be available to analyzer and outcome assessor as A, B and C .</study_design>
      <phase>N/A</phase>
      <hc_freetext>Plantar fasciitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Dry needling of plantar fascia: Routine physiotherapy interventions including ultrasound with 3 MHz intensity (for 5 minutes for the painful point of plantar fascia), low frequency TENS with 120 Hz frequency and 40 milli seconds duration ( for 15 minutes to the same painful spot) are applied for people with plantar fasciitis (15 people) before applying dry needling.This technique is performed twice a week for two consecutive weeks, while the patient is in prone position, the skin is cleaned and 15 stainless steel needles with a length and diameter of 0.25 x 40 millimeter are inserted into the plantar fascia, which is considered the most painful area in plantar fasciitis. The needles are guided 0.5 to 1.5 cm through the skin and fascia, and are applied with consecutive strokes and keeping the needle in place for 10 minutes and rotating 3-4 times.This rotation method is repeated twice in each step. After the needles are removed, the needle insertion sites are tightly compressed to prevent bleeding. Intervention 2: Intervention group 2: Plantar fascia kinesiotape: Routine physiotherapy interventions including ultrasound with 3 MHz intensity (for 5 minutes for the painful point of plantar fascia), low frequency TENS with 120 Hz frequency and 40 milliseconds duration (for 15 minutes for the same painful point) is applied for people with plantar fasciitis (15 people) before applying kinesiotape . To perform kinesiotape, Tex Tape with 25% tension is used for plantar fascia. Tapping is used for patients twice a week for two weeks.  During tape application, the patient is placed in prone position, and the knee joints are placed in 90 degree flexion and the ankle joints are placed in a normal position. The strip is cut longitudinally into four slices of equal width. The strip is marked on the Achilles tendon or the dorsal border of the calcaneus. Four spots are identified on the first to fifth metatarsals  joints, except the third metatarsal joint. Finally, it is applied by the space correction method, with 25% stretching of the forefoot. The initial length of the tape will be approximately half the length of the foot, measured from the end of the heel to the tip of the big toe. Intervention 3: Control group: routine physiotherapy: Routine physiotherapy is performed 5 days a week for two weeks for people with plantar fasciitis (15 people). Routine physiotherapy interventions include ultrasound therapy and low frequency TENS for plantar fascia.  Ultrasound with 3 MHz  intensity and for 5 minutes is applied to the painful point of the plantar fascia. Low frequency TENS with 120 Hz frequency and 40 milliseconds duration is applied for 15 minutes to the same painful point.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Mokhtari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.19,  Abmorad street</address>
        <city>Cholicheh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88671-87930</zip>
        <telephone>+98 38 3326 7355</telephone>
        <email>maryam.mokhtari444@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Mokhtari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.19, Abmorad street</address>
        <city>Cholicheh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88671-87930</zip>
        <telephone>+98 38 3326 7355</telephone>
        <email>maryam.mokhtari444@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Plantar fasciitis
Heel pain with the most tenderness in the medial tubercle of foot
Pain more than 3 months in the medial tubercle
Pain level at least 3 in visual analog scale
Pain with  first step in the morning or after a long period of rest
Experience of pain despite other conservative methods (eg, silicone insoles, nonsteroidal anti-inflammatory drugs, and exercise)
Without cognitive disorder and consciousness disorder
The thickness of the fascia is more than 4 mm
Sign the consent form
Age between 18-60 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Positive sign of sciatica in sciatica nerve test
Allergic to kinesiotape
Medical diagnosis of gout, diabetic neuropathy, rheumatoid arthritis, lupus, cancer and infection
Allergic or fear of dry needles (DN)
Presence of peripheral arterial vascular disease
Pregnancy
Plantar heel pain treatment with DN or acupuncture in last 4 weeks
History of heart diseases
History of corticosteroid injection in the heel in the last 3 months
History of chemotherapy in the last six months
Heel spur
Plantar hyper hydrosis
Hyper activity
Skin disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M72.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other fibroblastic disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Dry needling of plantar fascia: Routine physiotherapy interventions including ultrasound with 3 MHz intensity (for 5 minutes for the painful point of plantar fascia), low frequency TENS with 120 Hz frequency and 40 milli seconds duration ( for 15 minutes to the same painful spot) are applied for people with plantar fasciitis (15 people) before applying dry needling.This technique is performed twice a week for two consecutive weeks, while the patient is in prone position, the skin is cleaned and 15 stainless steel needles with a length and diameter of 0.25 x 40 millimeter are inserted into the plantar fascia, which is considered the most painful area in plantar fasciitis. The needles are guided 0.5 to 1.5 cm through the skin and fascia, and are applied with consecutive strokes and keeping the needle in place for 10 minutes and rotating 3-4 times.This rotation method is repeated twice in each step. After the needles are removed, the needle insertion sites are tightly compressed to prevent bleeding.</i_keyword>
      <i_keyword>Intervention group 2: Plantar fascia kinesiotape: Routine physiotherapy interventions including ultrasound with 3 MHz intensity (for 5 minutes for the painful point of plantar fascia), low frequency TENS with 120 Hz frequency and 40 milliseconds duration (for 15 minutes for the same painful point) is applied for people with plantar fasciitis (15 people) before applying kinesiotape . To perform kinesiotape, Tex Tape with 25% tension is used for plantar fascia. Tapping is used for patients twice a week for two weeks.  During tape application, the patient is placed in prone position, and the knee joints are placed in 90 degree flexion and the ankle joints are placed in a normal position. The strip is cut longitudinally into four slices of equal width. The strip is marked on the Achilles tendon or the dorsal border of the calcaneus. Four spots are identified on the first to fifth metatarsals  joints, except the third metatarsal joint. Finally, it is applied by the space correction method, with 25% stretching of the forefoot. The initial length of the tape will be approximately half the length of the foot, measured from the end of the heel to the tip of the big toe.</i_keyword>
      <i_keyword>Control group: routine physiotherapy: Routine physiotherapy is performed 5 days a week for two weeks for people with plantar fasciitis (15 people). Routine physiotherapy interventions include ultrasound therapy and low frequency TENS for plantar fascia.  Ultrasound with 3 MHz  intensity and for 5 minutes is applied to the painful point of the plantar fascia. Low frequency TENS with 120 Hz frequency and 40 milliseconds duration is applied for 15 minutes to the same painful point.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Plantar fascia thickness in patient with Plantar fasciitis. Timepoint: The measurement of the thickness of the plantar fascia is done at the beginning of the study (before the start of the intervention) and 2 and 4 weeks after the start of the interventions. Method of measurement: To measure the  plantar fascia thickness, an ultrasound machine model HS2100 made in Japan with a frequency of 12 MHz and a linear probe of 4.5 cm is used. The transducer of the ultrasound device is placed in the sagittal plane on the inner band of the plantar fascia at the junction with the inner prominence of the heel, and the thickness of the plantar fascia is measured.</prim_outcome>
      <prim_outcome>Pain score in patient with Plantar fasciitis. Timepoint: The measurement of pain score is done at the beginning of the study (before the start of the intervention) and 2 and 4 weeks after the start of the interventions. Method of measurement: The basis of pain is based on the visual analog scale that is used to measure and grade pain in patients.  In general, this scale is drawn as a 100 mm or 10 cm line, and the amount of pain is rated between 0 and 10.The two ends of the scale include the number zero at the left which indicates no pain (zero = no pain) and the number 10 at the right end indicates the most pain.  The number 1 to 3 indicates mild pain, the number 4 to 6 indicates moderate pain, and the number 7 to 10 indicates severe pain. The patient marks his pain score with a vertical line on the scale.</prim_outcome>
      <prim_outcome>Performance score in patient with Plantar fasciitis. Timepoint: The measurement of performance score is done at the beginning of the study (before the start of the intervention) and 2 and 4 weeks after the start of the interventions. Method of measurement: The Foot and Ankle Outcome Score (FAOS) questionnaire is used to evaluate performance in this research. This questionnaire is designed to evaluate symptoms and functional limitations related to the foot and ankle. This questionnaire asks for patient's ankle problem and helps to know how the patient feels about his ankle and to what extent he is able to perform his usual activities. It has five subscales: pain, symptoms (stiffness, swelling, crepitus, and movement limitation), performance in activities of daily living (ADL), performance in sports, and quality of life (QoL). Scores of 0 and 100 represent severe and asymptomatic symptoms, respectively.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-24</approval_date>
        <contact_name>Ethics committee of semnan University of Medical Sciences</contact_name>
        <contact_address>Headquarter of Semnan University of Medical Sciences and Health Services, Basij Blvd, Semnan, Iran. Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
